Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions

Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions

Author Rangel, Erika B. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Albert Einstein Hosp
Abstract Introduction: With further reduction in surgical complications and improvement in immunosuppressive protocols, pancreas transplant offers excellent outcomes for patients with diabetes. However, long-term survival of pancreas allograft is affected not only by rejection but also by immunosuppressive regimen toxicity.Areas covered: This article reviews the existing literature and knowledge of tacrolimus toxicity and focuses on its diabetogenic effect after pancreas transplant. Some clinically relevant drug-drug interactions with glucocorticoids and sirolimus are also highlighted. This review also summarizes the diabetogenic mechanisms of tacrolimus, the alternatives to minimize these effects, and the main differential diagnosis of hyperglycemia after pancreas transplant.Expert opinion: Tacrolimus is a potent calcineurin inhibitor, an important pathway that regulates pancreatic development. Tacrolimus can induce beta-cell apoptosis, decrease insulin exocytosis and reduce insulin gene transcription, which ultimately lead to impaired functional beta-cell mass after pancreas transplant. Furthermore, insulin resistance can exacerbate the diabetogenic effect of tacrolimus due to inhibition of insulin gene transcription and beta-cell proliferation. It is important to critically analyze the results of clinical studies and investigate new immunosuppressive drugs and/or novel drug combinations. It is equally important to comprehend and interpret experimental data. Therefore, minimization of side effects, based on safe approaches, can prolong pancreas allograft survival.
Keywords hyperglycemia
new-onset of diabetes after transplant
pancreas transplant
post-transplant diabetes mellitus
Language English
Date 2014-11-01
Published in Expert Opinion On Drug Metabolism & Toxicology. London: Informa Healthcare, v. 10, n. 11, p. 1585-1605, 2014.
ISSN 1742-5255 (Sherpa/Romeo, impact factor)
Publisher Informa Healthcare
Extent 1585-1605
Origin http://dx.doi.org/10.1517/17425255.2014.964205
Access rights Closed access
Type Review
Web of Science ID WOS:000343976500008
URI http://repositorio.unifesp.br/handle/11600/38438

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account